Navigation Links
Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
Date:7/8/2009

SAN FRANCISCO, July 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has received commitments from investors to purchase in a private placement securities of the Company for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer, acted as the exclusive placement agent for the transaction.

The net proceeds of the financing will be used to support the advancement of Nile's lead compound, CD-NP, through its 30-patient single-blind, placebo-controlled Phase 2 study, which is currently open to enrollment. This Phase 2 study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function.

"We are pleased to have the continued support of the investment community to ensure the advancement of our promising technology in the effort to develop a novel treatment for heart failure patients," said Joshua Kazam, Chief Executive Officer. "We believe these funds will provide us with sufficient capital to complete our impending Phase 2 clinical study of CD-NP and we look forward to generating meaningful clinical data."

Under the terms of a Securities Purchase Agreement, Nile will sell an aggregate of approximately 2.7 million shares of its common stock and warrants to purchase up approximately 2.7 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase one share of comm
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire/ ...search report is available in its catalogue: ,,...pe: Market dynamics and the changing healthcare an...linker.com/p0165658/Emerging-Clinical-Trial-Locati...ing-healthcare-and-regulatory-environment.html ,...
(Date:12/1/2009)... , , Former Majority Leader Richard ...Science, Medicine, Biotech Communities for "Best ... JERSEY CITY, N.J., Dec. 1 /PRNewswire-USNewswire/... in biopharmaceuticals, research, medicine and tec...er to discuss the importance of medical innovation...
(Date:12/1/2009)... , , SPRINGFIELD, Ill., Dec. 1 /PRNews...), is proud to announce that it was recently award...e Awards event on Nov. 13 in New York City. The CL...e and innovation in the healthcare advertising ind...of the world,s most recognized awards competitions...
(Date:12/1/2009)... , EpiVax, Inc. today ann...he (SIX: RO, ROG; OTCQX: RHHBY) aimed at evaluatin... which could potentially reduce detrimental immune...Roche-EpiVax collaboration, the EpiVax Tregitope t... immunogenicity of protein therapeutics. , ...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3
...vate Placement of Convertible Preferred Stock -, ... Bulletin Board: ACCP) announced today that it has...y. The Company has entered into agreements,with in...n aggregate of,$2.7 million in gross proceeds of t... This equity is in addition to the $9.5 million in...
...H, Ga. and RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,...that they have signed an,agreement under which Mer...imal health drug leads. Under the terms of this ag...se with Chimerix for leads identified for,possible...merix provides us with an opportunity to,further e...
...IEGO, Jan. 29 ChemDiv, Inc., a leading,chemistry-...announced today,that it has entered into a discove...ncisco, CA. Applying its expertise in medicinal an...en in identifying and developing,novel antibacteri... were,not disclosed., "We look forward to collabo...
Other Biology Technology:Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2ChemDiv and Achaogen Enter Into a Discovery Collaboration 2
(Date:12/2/2009)...d are more likely to go on to university, reveals ...cademy and Sahlgrenska University Hospital. , Th... Proceedings of the National Academy of Sciences ...en doing military service who were born between 19...ts of both physical and IQ tests when the men enro...
(Date:12/2/2009)...ct called moist snuff placed between lip and gum ...co industry to change manufacturing practices to r...is published online in ACS, monthly journal Chemi...category of tobacco products contains surprisingly...ubstances. Called polycyclic aromatic hydrocarbons...
(Date:12/2/2009)...d PALM HARBOR, Fla., Dec. 2 /PRNewswire-FirstCall/... (OTC Bulletin Board: CICI), a leading supplier of...ss automation in the financial industry* and the r...tion and Docubase Systems Inc. ("Docubase"), a lea...(EDM) software provider announced today that they ...
Breaking Biology News(10 mins):Young adults who exercise get higher IQ 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Imagenetix Inc Reports First Quarter 2010 Results 13476 1Imagenetix Inc Reports First Quarter 2010 Results 13476 2Imagenetix Inc Reports First Quarter 2010 Results 13476 3Imagenetix Inc Reports First Quarter 2010 Results 13476 4Imagenetix Inc Reports First Quarter 2010 Results 13476 5Breast Feeding May Lower Breast Cancer Risk 54103 1Breast Feeding May Lower Breast Cancer Risk 54103 2Breast Feeding May Lower Breast Cancer Risk 54103 3The Elephant in the Room 3A Panel on Immigrations Impact on Health Care Reform 54098 1
...alias extinct marsupial lion (Thylacoleo carnifex)... (Panthera leo) had the two big hyper-carnivores e... to an Australian scientist. , New research publi...coleo killed prey rapidly, using its bolt-cutter t...duce major trauma and blood loss. , By contrast,...
...lowers itself to death and exists as part of an en...car; its name will be published in the Botanical J...The mystery palm has a huge trunk which towers ove... ?among the largest known in flowering plants. Thi...agascar. , The plant has an unusual and spectacu...
...008) The latest medications can delay the onset o...e its devastating effects. This limitation often m...s maintaining a good quality of life for as long a... Georgia Institute of Technology and Emory Univers...e test that could be administered as part of a rou...
Other Biology News:Marsupial lion tops African lion in fight to death 2New genus of self-destructive palm found in Madagascar 2New genus of self-destructive palm found in Madagascar 3Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3
Feline IL-2 ELISpot Kit from R&D Systems
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids* from Molecular Probes (Invitrogen)
Anti-Potassium Channel, TASK (TWIK-Related Acid Sensitive, TASK-1, cTBAK, Kcnk3) Polyclonal Antibody, Unconjugated from CHEMICON
Rat Anti-Kinase Suppressor Of Ras Monoclonal Antibody, Unconjugated, Clone MINT/1/4 from GeneTex
Biology Products: